viewMota Ventures

Mota Ventures trumpets Nature's Exclusive CBD revenue growth, German psychedelic acquisition in conference call

In a call with investors Wednesday, Mota announced that the CBD brand saw revenue of C$29 million and net income of C$3.5 million in 2019

$100 bill appearing to grow from a cannabis plant
Mota recently acquired Verrian, which owns a 110,000 square foot pharmaceutical manufacturing facility in Germany

Mota Ventures Corp (CSE:MOTA) (OTCPINK:PEMTF) updated investors Wednesday on the company’s recent audit of its Nature’s Exclusive brand of CBD products and its recent acquisition of the German psychedelic medicine company Verrian Ontario Ltd.

In a conference call after the bell, Mota announced that Nature’s Exclusive, which serves consumers in the US and Europe, saw revenue of C$29 million and net income of C$3.5 million in 2019, while associated expenses were C$25.5 million.

This year, the company has already brought in revenue of more than C$13.9 million for the months of January through April, almost triple the amount it it made over the same period last year. Related expenses were C$13.5 million.

READ: Mota Ventures says Nature's Exclusive brand produced C$3.5M in net income in 2019

Mota is managing to rack up new customers too, with more than 17,613 new customers in May alone, more than 60% of whom opted for a subscription. 

On the psychedelics front, the company jumped into what it called “overwhelming momentum” in the sector with the recent acquisition of Verrian, which owns a 110,000 square foot pharmaceutical manufacturing facility in Germany.

The facility and its equipment have been independently appraised at C$10.6 million, the company said, including an analytical laboratory and full pharmaceutical manufacturing suite.

"Our acquisition of Verrian is another step forward in executing our vision to use our powerful eCommerce platform for new and innovative natural health products,” CEO Ryan Hoggan said in a statement. “While we continue to grow and expand our CBD business units, we will also be ready to fully commercialize the technology created by Verrian.”

That process is already underway. The business has invested more than C$2 million in clinical trials with two studies already ongoing, Mota said.

Verrian’s pipeline includes PSI Gen and PSI Gen+, natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs designed to achieve opioid addiction reduction. 

Hoggan believes Mota and Verrian can take a holistic approach in helping to curb the opioid epidemic.

“I look forward to working with Verrian's incredibly talented team of clinical researchers and addiction medicine professionals within our existing ecosystem as it will uniquely position us as a leader in psychedelic medicine," he said.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Mota Ventures

Price: 0.245 CAD

Market: CSE
Market Cap: $24.43 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Mota Ventures named herein, including the promotion by the Company of Mota Ventures in any Content on the Site, the Company receives from said...



Full interview: Mota Ventures sees strong sales increase amid COVID-19 Crisis

Mota Ventures (CSE: MOTA-OTCMKTS: PEMTF) CEO Ryan Hoggan joined Steve Darling from Proactive Vancouver to discuss how the company is doing during the Corona Virus crisis and how it has affected sales. Hoggan also told Proactive about a new product line the company has started and how excited...

on 1/4/20

2 min read